Cara Therapeutics Inc (NASDAQ:CARA)
| 13.22 Delayed Data As of Oct 28 |  -0.54 / -3.92%Today’s Change | 8.88 Today|||52-Week Range 26.67 | -17.94% Year-to-Date |
Latest CARA News | Press Releases
| Cara (CARA) Moves to Buy: Rationale Behind the Upgrade Oct 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 13.76 |
| Today’s open | 13.50 |
| Day’s range | 13.02 - 13.50 |
| Volume | 12,956 |
| Average volume (3 months) | 401,227 |
| Market cap | $668.6M |
Data as of 3:58pm ET, 10/28/2020
Growth & Valuation
| Earnings growth (last year) | -20.90% |
| Earnings growth (this year) | +5.42% |
| Earnings growth (next 5 years) | -66.83% |
| Revenue growth (last year) | +47.64% |
| P/E ratio | NM |
| Price/Sales | 34.57 |
| Price/Book | 3.57 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RDUSRadius Health Inc | -0.36 | -2.61% |
| BCRXBioCryst Pharmaceuti... | -0.08 | -2.02% |
| KDMNKadmon Holdings Inc | -0.13 | -3.59% |
| VXRTVaxart Inc | -0.44 | -8.09% |
Data as of 3:59pm ET, 10/28/2020
Financials
| Last reporting date | October 29, 2020 |
| EPS forecast (this quarter) | -$0.60 |
| Annual revenue (last year) | $19.9M |
| Annual profit (last year) | -$106.4M |
| Net profit margin | -534.91% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Stamford, Connecticut |
Forecasts
